Vaxcyte (PCVX) News Today → Missed NVDA? Buy this AI stock NOW (From Chaikin Analytics) (Ad) Free PCVX Stock Alerts $74.57 -0.88 (-1.17%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 5:23 AM | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)Charles Schwab Investment Management Inc. grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 730,438 shares of the comMay 19 at 4:22 AM | americanbankingnews.comReviewing Cognition Therapeutics (NASDAQ:CGTX) and Vaxcyte (NASDAQ:PCVX)May 17 at 4:55 AM | marketbeat.comNatixis Advisors L.P. Invests $881,000 in Vaxcyte, Inc. (NASDAQ:PCVX)Natixis Advisors L.P. purchased a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 14,035 shares of the company's stock, valued at approximately $88May 16 at 8:04 PM | marketbeat.comVaxcyte (NASDAQ:PCVX) Trading 5.5% Higher Vaxcyte (NASDAQ:PCVX) Trading 5.5% HigherMay 15, 2024 | marketbeat.comNicholas Investment Partners LP Trims Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)Nicholas Investment Partners LP lessened its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 75.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 110,723 shares of the company's stock after selling 349,285 shares during tMay 13, 2024 | americanbankingnews.comVaxcyte (NASDAQ:PCVX) Stock Rating Reaffirmed by Needham & Company LLCMay 13, 2024 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) Expected to Earn Q2 2024 Earnings of ($1.00) Per ShareMay 10, 2024 | finance.yahoo.comVaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational OverviewMay 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Vaxcyte Amid Financial Discipline and Promising Vaccine TrialsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vaxcyte Amid Promising Pipeline and Clear MilestonesMay 9, 2024 | marketbeat.comVaxcyte (NASDAQ:PCVX) Releases Earnings Results, Beats Estimates By $0.28 EPSVaxcyte (NASDAQ:PCVX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.28.May 9, 2024 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research report on Thursday.May 9, 2024 | marketbeat.comVictory Capital Management Inc. Has $23.83 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)Victory Capital Management Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 12.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 379,407 shares of the company's stock afterMay 8, 2024 | investorplace.comPCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024May 8, 2024 | globenewswire.comVaxcyte Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 4, 2024 | finance.yahoo.comInsider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 SharesApril 26, 2024 | marketbeat.comabrdn plc Takes $12.20 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX)abrdn plc acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 194,232 shares of the company's stock, valued at approximately $12,198,000. abrdn plc ownedApril 26, 2024 | insidertrades.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 15,000 Shares of StockApril 25, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $928,800.00 in StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total value of $928,800.00. Following the completion of the transaction, the chief executive officer now directly owns 477,847 shares in the company, valued at approximately $29,588,286.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.April 24, 2024 | finance.yahoo.comVaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - Yahoo FinanceApril 24, 2024 | investing.comVaxcyte president and CFO sells shares worth over $490kApril 23, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Jennison Associates LLCJennison Associates LLC reduced its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 15.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,476,154 shares of the company's stock after selling 278,537 shares during the period. Jennison Associates LLC ownApril 23, 2024 | insidertrades.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of StockApril 22, 2024 | marketbeat.comAndrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total transaction of $490,160.00. Following the completion of the sale, the chief financial officer now directly owns 95,679 shares of the company's stock, valued at $5,862,252.33. The transaction was disclosed in a filing with the SEC, which is available at this link.April 21, 2024 | finance.yahoo.comVaxcyte, Inc. (PCVX)April 19, 2024 | marketbeat.comMutual of America Capital Management LLC Acquires New Shares in Vaxcyte, Inc. (NASDAQ:PCVX)Mutual of America Capital Management LLC acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 48,330 shares of the company's stock, valued at aApril 14, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - PCVXApril 10, 2024 | msn.comVaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst SaysApril 2, 2024 | globenewswire.comVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 29, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of "Buy" by AnalystsVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has earned an average recommendation of "Buy" from the five brokerages that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that haveMarch 28, 2024 | insidertrades.comGrant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockMarch 27, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 15,000 SharesVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Monday, March 25th. The stock was sold at an average price of $66.93, for a total value of $1,003,950.00. Following the sale, the chief executive officer now directly owns 477,847 shares of the company's stock, valued at approximately $31,982,299.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.March 25, 2024 | marketbeat.comVanguard Group Inc. Buys 47,872 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Vanguard Group Inc. boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 0.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,284,246 shares of the company's stockMarch 20, 2024 | finance.yahoo.comInsider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 SharesMarch 20, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 SharesVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $69.02, for a total transaction of $552,160.00. Following the sale, the chief financial officer now directly owns 95,679 shares in the company, valued at approximately $6,603,764.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.March 19, 2024 | marketbeat.com86,431 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Bought by Comerica BankComerica Bank purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 86,431 shares of the company's stock, valued at approximately $4,4March 16, 2024 | ca.finance.yahoo.comPCVX Jul 2024 70.000 putMarch 16, 2024 | ca.finance.yahoo.comPCVX Apr 2024 80.000 putMarch 16, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Citigroup Inc.Citigroup Inc. raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 21.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 95,439 shares of the company's stock after purchasing an additional 16,816 shares during the quarMarch 16, 2024 | finance.yahoo.comPCVX Apr 2024 100.000 callMarch 15, 2024 | marketbeat.comWellington Management Group LLP Acquires 167,501 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Wellington Management Group LLP grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 3.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,598,712 shares of the company's stock after buying an additional 167,5March 14, 2024 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Sees Large Decline in Short InterestVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 29th, there was short interest totalling 8,460,000 shares, a decrease of 20.6% from the February 14th total of 10,650,000 shares. Based on an average trading volume of 905,000 shares, the days-to-cover ratio is presently 9.3 days.March 12, 2024 | msn.comOracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For TuesdayMarch 10, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Increases Position in Vaxcyte, Inc. (NASDAQ:PCVX)Adage Capital Partners GP L.L.C. raised its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 119.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 132,088 shares of the company's stock after purcMarch 9, 2024 | marketbeat.comGlenmede Trust Co. NA Acquires Shares of 14,938 Vaxcyte, Inc. (NASDAQ:PCVX)Glenmede Trust Co. NA bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 14,938 shares of the company's stock, valued at approximately $762,000. Other laMarch 4, 2024 | finanznachrichten.deVaxcyte, Inc.: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsMarch 4, 2024 | globenewswire.comVaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsMarch 4, 2024 | marketbeat.comNorthern Trust Corp Boosts Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)Northern Trust Corp boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 4.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 896,635 shares of the company's stock aftMarch 2, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Buys 23,943 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Schonfeld Strategic Advisors LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 9.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 266,021 shares of the company's stock after buying an additional 23,943 shares during the periMarch 1, 2024 | marketbeat.comBraidwell LP Has $82.57 Million Stake in Vaxcyte, Inc. (NASDAQ:PCVX)Braidwell LP trimmed its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 6.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,619,553 shares of the company's stock after selling 102,800 s Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. PCVX Media Mentions By Week PCVX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCVX News Sentiment▼0.430.42▲Average Medical News Sentiment PCVX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCVX Articles This Week▼103▲PCVX Articles Average Week Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Exelixis News Today Revolution Medicines News Today ImmunityBio News Today Halozyme Therapeutics News Today Repligen News Today CRISPR Therapeutics News Today Krystal Biotech News Today Qiagen News Today Immunovant News Today SpringWorks Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCVX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
